Bolivia MERCOSUR Membership: The Four-Year Acquis Adoption Window for Medical Devices

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Bolivia deposited its instrument of ratification of the Accession Protocol on July 8, 2024, becoming a full member of MERCOSUR (the Southern Common Market); Article 3 of the Accession Protocol requires the progressive adoption of the current MERCOSUR regulatory acquis within a maximum of 4 years from the entry into force of the protocol, and public technical cooperation documents disclose a pending stock of approximately 3,974 norms and 84 agreements. The variable most directly relevant to device companies is MERCOSUR Common Market Group (GMC) Resolución N° 25/21, the technical regulation on the registration of medical device products — already implemented in Argentina through Resolución N° 64/2025 (January 2025). GRZAN’s assessment: Bolivia’s current structure of registration by group, self-declared risk level, and manual-based documentation faces a possible migration toward the MERCOSUR common documentation format within the absorption window, and technical documentation should be built to be migratable.

The acquis adoption exercise is large by any measure — approximately 3,974 norms and 84 agreements disclosed in public technical cooperation documents — and device rules sit inside it as one sector among many. Sequencing is therefore unpredictable: the transposition of GMC Resolución N° 25/21 competes with every other adoption obligation under Article 3 of the Accession Protocol, and the practical date of the Bolivian format switch cannot be fixed in advance. What can be fixed is the company’s own readiness, which is why GRZAN frames this page around documentation architecture rather than around predictions.

2. Legal basis

RegulationReferencePublication dateProvision
Protocolo de Adhesión de Bolivia al MERCOSUR (Accession Protocol)MERCOSUR Accession ProtocolInstrument of ratification deposited July 8, 2024Article 3
Resolución GMC N° 25/21 (MERCOSUR technical regulation on medical device product registration)GMC Resolución N° 25/212021Full text
Resolución (Argentine adoption of GMC 25/21)Resolución N° 64/2025January 2025Full text
Manual para Registro Sanitario de Dispositivos MédicosResolución Ministerial N° 010As per the current version published on the AGEMED websiteSection 1.2

The instruments form a chain of waiting transposition. The Accession Protocol creates the obligation and the 4 year clock; GMC Resolución N° 25/21 defines the destination format for device registration; Resolución N° 64/2025 shows what a completed national adoption looks like in a neighbouring economy; and Section 1.2 of the national manual remains, for now, the scope provision actually governing Bolivian submissions.

The Argentine implementation is the region’s worked example. Resolución N° 64/2025, adopted in January 2025, brings GMC Resolución N° 25/21 into national law there, and its structure shows what an adopting regulator actually inherits: a common technical regulation for device product registration, common documentation expectations, and a common vocabulary for classification. For planning purposes, the Argentine text is the most concrete preview available of the format Bolivian files may eventually need to follow.

3. Expert insights

Insight 1: this is a variable that is about to take effect, not one already in effect. MERCOSUR membership is settled, but the transposition of GMC Resolución N° 25/21 into Bolivia has not yet occurred. GRZAN does not recommend filing Bolivian applications in MERCOSUR format now — the current valid basis remains the national manual. The correct action is to build flexibility into the documentation architecture.

Insight 2: the absorption window gives companies a concrete planning anchor. Counting 4 years from July 2024, the window falls around mid-2028. Companies preparing 5-year plans should assume one documentation-format switch inside the window and design the technical file as a modular structure accordingly.

Insight 3: dual regional membership creates rule competition. Bolivia is simultaneously a member of CAN and of MERCOSUR. The two regions harmonise device rules along different paths, and which set Bolivia ultimately adopts — or how the two coexist — is the structural question most worth tracking over the next 24 months. GRZAN lists it as the first tracking item of its evergreen monitoring series.

The dual-membership question deserves explicit monitoring because it is genuinely open. Bolivia’s obligations under the CAN framework continue in parallel with its MERCOSUR accession, and the two harmonisation projects are not automatically congruent. Whether AGEMED eventually administers one merged national rulebook, two parallel regimes by product origin, or a staged transition is not decided in any text available today, and prudent 5-year plans should carry that uncertainty as a scenario branch rather than as a single forecast.

4. Practical recommendations

  1. Build the technical file modularly: keep classification argumentation, clinical evidence, quality system, and labelling as four independent volumes that can be reassembled under a future format.
  2. Reserve budget and hours for one format switch inside the 5-year plan.
  3. Include MERCOSUR transposition progress in quarterly regulatory tracking, watching documents issued by AGEMED and the foreign ministry.

Modularity is cheap now and expensive later. Splitting the technical file into self-contained volumes costs little more than disciplined formatting today, whereas retrofitting a monolithic file into a new regulatory template after a transposition decree usually means re-editing every section under deadline pressure. The same modularity also simplifies submissions to other MERCOSUR markets once the national adoption is complete.

For dossier teams, the near-term checklist is modest: keep the four volumes of the technical file independently paginated and independently versioned, log which sections map to manual provisions and which map to MERCOSUR format elements, and re-verify the transposition status each quarter. None of this changes today’s submissions — they remain governed by the national manual — but all of it shortens the migration when the decree arrives, which is the entire point of preparing in advance.

5. Verification checklist

  • □ Confirm the 4 year absorption period under Article 3 of the MERCOSUR Accession Protocol has been verified
  • □ Confirm the transposition status of GMC Resolución N° 25/21 in Bolivia has been checked
  • □ Confirm the technical file has been built with a modular structure
  • □ Confirm the 5-year plan includes one documentation-format switch assumption
  • □ Confirm MERCOSUR transposition progress is on the quarterly tracking list

GRZAN registration support. GRZAN provides medical device registration support in Bolivia for manufacturers, importers, and authorized representatives, including MERCOSUR-readiness assessment and modular technical file design. For project inquiries, contact info@grzanglobal.com.

Regulatory information verified as of October 29, 2026.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail